Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management
Elizabeth Braunlin(University of Minnesota), Roberto Giugliani(Instituto de Biologia Molecular e Celular), Maurizio Scarpa(University of Udine), William C. Roberts(Baylor University Medical Center), Christoph Kampmann(University Children's Hospital Tübingen), James P. Loehr(University of North Carolina at Chapel Hill), Katherine P. Ponder(Washington University in St. Louis), Paul Harmatz(Royal Manchester Children's Hospital), Howard M. Rosenfeld, Beatriz Helena Furlanetto(Beneficência Portuguesa de São Paulo)
Cited by 302
Related Papers
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555
Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
|European Journal of Pediatrics|2007|522
Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study
|The Journal of Pediatrics|2006|364
Immunologic Privilege in the Central Nervous System and the Blood–Brain Barrier
|Journal of Cerebral Blood Flow & Metabolism|2012|307
Possible strategies to cross the blood–brain barrier
|The Italian Journal of Pediatrics/Italian journal of pediatrics|2018|255